The Miami longevity startup says it hopes to reach human trials during the nine-month program, after extensive preclinical development. #longevity# #humantrials# #preclinical# #Miami# #startup#

🚨 A groundbreaking stem cell nerve therapy has officially entered human trials to reverse paralysis caused by spinal cord injuries. The treatment, called XS228, uses lab-grown neurons derived from induced pluripotent stem cells (iPSCs). These cells are reprogrammed from adult donors and transformed into neural precursors capable of regenerating damaged spinal tissue. In preclinical studies, the therapy helped paralyzed animals regain movement by growing new axons and forming connections with host nerve cells. Now, researchers in China have launched the world’s first registrational trial to test its safety and effectiveness in humans. If successful, this could be a game-changer, offering a scalable, off-the-shelf solution to restore mobility and independence for millions affected by spinal cord injuries. This marks a historic step in regenerative medicine, offering new hope to the millions living with spinal cord injuries worldwide.

Genesis Molecular AI CTO @edunov breaks down how a drug goes from 20,000 possible protein targets to human trials: "First step is target identification. There are 20,000 proteins in our bodies, and sometimes they malfunction. What we often need to do is either activate or deactivate those proteins." "Next step is hit ID: a molecule that sticks to this protein and doesn't stick to everything else. Then you optimize for certain properties." "For a pill, it needs to be soluble in water. Stable on the shelf and in your body, so it's not digested and excreted right away. If it's in the brain, your drug needs to penetrate the blood-brain barrier." "Then finally, with a drug candidate, you start experiments in animals and then in humans." @genesismolai

Wellness influencers are citing studies that don't exist. The ‘Wolverine Stack?’ Zero human trials. Reuters Misinformation Monitor reveals how fake medical claims are being used to sell unapproved treatments. Subscribe to stay ahead of what's happening 📩

Wellness influencers are citing studies that don't exist. The ‘Wolverine Stack?’ Zero human trials. Reuters Misinformation Monitor reveals how fake medical claims are being used to sell unapproved treatments. Subscribe to stay ahead of what's happening 📩

Wellness influencers are citing studies that don't exist. The ‘Wolverine Stack?’ Zero human trials. Reuters Misinformation Monitor reveals how fake medical claims are being used to sell unapproved treatments. Subscribe to stay ahead of what's happening 📩

This is a dog with a myostatin deficiency, which roughly doubles its muscle mass. Myostatin is a protein every mammal makes to stop muscle growing past a certain point. There are now drugs in human trials that block myostatin on purpose to stop people from losing muscle with age or on GLP-1s. I think myostatin inhibitors may end up as one of the biggest drug classes of the next decade.

Anthropic has acquired Mithril Medicine, a one-person biotech startup, and is now running drug discovery programs of its own. Founder Cody Tranbarger used Claude to coordinate contracts, logistics and experiments with 11 external labs. Anthropic says that work took a potential treatment for a rare form of muscular dystrophy from an idea to promising results in mice in under 18 months. Mithril has been developing treatments for two rare forms of muscular dystrophy. Tranbarger is continuing the research at Anthropic, which says a drug could be ready to start human trials as early as late 2028 if the candidates continue to hold up. Anthropic also announced research partnerships with six organizations, including Bristol Myers Squibb, Generate Biomedicines and Enveda. The work spans drug design, manufacturing, regulatory documentation and clinical trial planning. Most of the research remains preclinical. The broader goal is to use Claude across the scientific and operational work required to move a potential medicine toward patients.